No usable source links are available for this idea. Its signal notes and scores need independent verification.
As seen when Samchundang Pharmaceutical announced a $380M contract inflated to $4B, bio-pharma technology licensing disclosures frequently overstate total values across upfront payments, milestones, and royalties. Individual investors and small-to-mid-sized asset managers ($7.5M–$37.5M AUM) lack the capacity to cross-verify original filings, contracts, and overseas partner IR materials, spending an average of 2–3 hours per trade decision and still frequently misjudging.
The tool auto-extracts contract amounts and terms from DART (Korean securities filing system) disclosures, cross-references them against overseas partner SEC/IR filings, and highlights discrepancies. It provides milestone-probability-weighted expected value calculations and peer benchmarks for comparable technology licensing deals.
| N Novelty | 1-5 | How uncommon the service is in market context. |
| U Urgency | 1-5 | How urgently users need this problem solved now. |
| M Market | 1-5 | Market size and growth potential from proxy indicators. |
| R Realizability | 1-5 | Buildability for a small team with realistic constraints. |
| V Validation | 1-5 | Validation signal quality from competition and demand data. |
| Tech Complexity | / 40 | Difficulty of core implementation stack. |
| Data Availability | / 25 | Practical availability and cost of required data. |
| MVP Timeline | / 20 | Expected time to ship a usable MVP. |
| API Bonus | / 15 | Bonus for viable public API leverage. |
| Competition | / 20 | Signal quality from competitor landscape. |
| Market Demand | / 20 | Demand proxies from search and mention patterns. |
| Timing | / 20 | Fit with current shifts in tech, behavior, and regulation. |
| Revenue Signals | / 15 | Reference evidence for monetization viability. |
| Pick-Axe Fit | / 15 | How well the concept serves participants in a trend. |
| Solo Buildability | / 10 | Practicality for lean-team implementation. |